Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Recruiting now · Not applicable

Conditions studied: Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma

In brief

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care) Participation in this research study is expected to last for up to 2 years. It is expected that about 90 people will take part in this research study.

Key facts

Study ID

NCT05646576

Run by

Massachusetts General Hospital

People needed

90

Starts

2022-12-30

Expected to finish

2027-04-01

Last updated by the study team

2026-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older.
• Ability to complete surveys in English or with assistance of an interpreter.
• Diagnosis of a hematologic malignancy.
• Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.

You may not qualify if…

• Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.
• Already receiving palliative care (PC).

Where it is running

• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.